Back to News
Market Impact: 0.2
Enlivex Therapeutics Ltd. Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra
Source: Nasdaq
Healthcare & Biotech
Enlivex Therapeutics said 135 of the planned 182 patients have been randomized and received their first Allocetra injection in its Phase 2b trial for moderate-to-severe [condition not specified in the provided text]. The update reports trial enrollment progress but provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
ENLV0.20
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics